Hainan Shuangcheng Pharmaceuticals
Hainan Shuangcheng Pharmaceuticals is a peptide manufacturer based in China (Haikou). Direct manufacturer. Founded 2000. Holds US DMFs for bivalirudin, eptifibatide, linaclotide, octreotide and 2 more API.
Listing reviewed October 2026.
About Hainan Shuangcheng Pharmaceuticals
Haikou-based maker of chemically synthesized peptide APIs and finished injectables, founded in 2000 and listed in Shenzhen (002693). Offers CDMO services and runs a second site in Ningbo. Its Haikou site has had four FDA inspections since 2013, each classed VAI. Holds active US Drug Master Files for bivalirudin, eptifibatide, linaclotide, octreotide, triptorelin and vasopressin API.
Directory assessment: Hainan Shuangcheng Pharmaceuticals is listed as a manufacturer in the peptide supply chain, serving Asia markets from China (Haikou). As a direct manufacturer, this supplier controls its own production process from synthesis through purification and quality control release testing. This profile lists 3 sources for reference. This supplier has a strong confidence score, indicating a high level of verification and reliability for B2B sourcing.
- Bivalirudin: DMF 30071 (Type II, active), submitted 2016-01-26
- Eptifibatide: DMF 31837 (Type II, active), submitted 2017-09-24
- Linaclotide: DMF 42040 (Type II, active), submitted 2025-06-12
- Octreotide: DMF 35816 (Type II, active), submitted 2021-11-26
- Triptorelin: DMF 39931 (Type II, active), submitted 2024-06-27
- Vasopressin: DMF 37634 (Type II, active), submitted 2022-12-03
DMF numbers from the FDA quarterly DMF list. A filed DMF is not FDA approval; its contents are confidential. Reviewed 2026-10-23.